Cyltezo

Generic name: adalimumab-adbm

Used for: Rheumatoid arthritis and juvenile arthritis (JIA) · Psoriatic arthritis · Ankylosing spondylitis (arthritis of the spine) · Crohn’s disease · Ulcerative colitis · Plaque psoriasis · Hidradenitis suppurativa (painful lumps under the skin) · Non-infectious uveitis (inflammation in the middle or back of the eye) · 7 more

How do you pay?

How to pay the least

Ask for the cash price

Cyltezo

Cyltezo is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

  1. Ask your pharmacy for Cyltezo’s cash price, and one or two other pharmacies too.

Compare every option

Question
Brand nameCyltezo
Authorized genericadalimumab-adbm
Regular genericadalimumab-adbm
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldAsk the pharmacy
Same as Cyltezo?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Cyltezo’s maker. Ask the pharmacy for Cyltezo’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Cyltezo itself, from the same company, sold without the brand name, and usually for less. For now Cyltezo is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

Cyltezo is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Cyltezo’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

CYLTEZO is a tumor necrosis factor (TNF) blocker indicated for:

  • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
  • Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.
  • Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.
  • Reducing signs and symptoms in adult patients with active ankylosing spondylitis.
  • Treatment of moderately to severely active Crohn's disease in adults and pediatric patients 6 years of age and older.
  • Treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use: Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers.
  • Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate.
  • Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.
  • Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older.

Source: the FDA label for Cyltezo (Boehringer Ingelheim Pharmaceuticals, Inc.), May 22, 2026. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/cyltezo/